Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial

Systemic Lupus Erythematosus Clinical Trial

Official title:

Efficacy and Safety of Low-dose Interleukin-2 in Patients With Systemic Lupus Erythematosus: a Multicenter, Randomised, Placebo-controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04077684
• Other study ID #: 2018PHB041-01
• Status: Recruiting
• Phase: Phase 2
• Start date: September 10, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: October 2023
• Source: Peking University People's Hospital
• Contact: Xia Zhang
• Phone: 8615201303563
• Email: haoxiamei[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The management of active systemic lupus erythematosus (SLE) is challenging due to the heterogeneous nature of the disease and lack of specific treatment. Current treatment regimens mainly rely on corticosteroids and immunosuppressive agents which are associated with substantial adverse effects including various infections. Therefore, there is an unmet need for new therapies with better efficacy and less adverse effects.

Defective IL-2 production contributes to the unbalanced immune system in SLE. Previous short term open-labelled trials showed that low-dose IL-2 was efficient and tolerated in active SLE. It was suggested that low-dose IL-2 treatment promoted regulatory T cells (Treg) and inhibited T helper 17 cells (Th17) and follicular helper T cells (Tfh). The immunological rebalancing was associated with the induction of remission in SLE patients.

To establish that which low doses of IL-2 would be more efficacious and safe in active SLE, we carried out a multi-center, randomized, double-blind, placebo-controlled trial of three doses of IL2 (0.2 MIU, 0.5 MIU or 1 MIU) versus placebo.

Description:

Active SLE patients at 18 to 75 years of age were enrolled. Patients were randomly assigned (in a 1:1:1:1 ratio) to one of the four arms (placebo or IL-2 at 0.2 MIU, 0.5 MIU or 1 MIU) in the study. IL-2 (0.2 MIU, 0.5 MIU or 1 MIU) or placebo was administered subcutaneously every other day for the first 12 weeks , and then was adjusted to once a week for the second 12 weeks. Follow-up visits occurred on weeks 4, 8,12,16,20 and 24. The end points were safety and clinical and immunologic response.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: December 31, 2024
• Est. primary completion date: August 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Meet the 1997 revised classification criteria of the American College of Rheumatology

2. SLE disease activity index(SLEDAI) = 8

3. age:18 to 75 years, weight 45-80Kg

4. Patients had an inadequate response to standard treatment for = 3 months. The background treatment included corticosteroids (=1.0 mg/kg), hydroxychloroquine, cyclophosphamide , mycophenolate mofetil or other immunosuppressants.

5. Negative urine pregnancy test

6. Written informed consent form

Exclusion Criteria:

1. allergic to IL-2, corticosteroids, hydroxychloroquine, cyclophosphamide or mycophenolate mofetil

2. active severe neuropsychiatric manifestations of SLE;

3. hepatic insufficiency (alanine aminotransferase or aspartate aminotransferase = 2 times of the upper limit of the normal range);

4. pregnancy or lactation in females.

5. Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or Basocellular carcinoma);

6. Serious infection such as bacteremia, sepsis;history of chronic infection;

7. active infection (hepatitis B or C virus, Epstein-Barr virus, human immunodeficiency virus or Mycobacterium tuberculosis);

8. history vision and visual field disorders, cataract;

9. severe comorbidities including heart failure (= grade III NYHA)

10. active peptic ulcers;

11. complicated with other autoimmune diseases;

12. History of administration of rituximab or other biologics within 6 months;

13. therapy with other immunosuppressors;

14. participate in other clinical trial within 4 weeks;

Related Conditions & MeSH terms

• Lupus Erythematosus, Systemic
• Systemic Lupus Erythematosus

Intervention

Drug:
• Interleukin-2
IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1

Locations

Country	Name	City	State
China	Peking University People's Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the response measured by the SLE Responder Index-4 (SRI-4)	SRI response was defined as (1) a = 4-point reduction in SELENA-SLEDAI score, (2) no new BILAG A score or = 1 new BILAG B score, and (3) no deterioration from baseline in the physician's global assessment by = 0.3 points.	week 12